The development of imatinib as a therapeutic agent for chronic myeloid leukemia
M Deininger, E Buchdunger, BJ Druker - Blood, 2005 - ashpublications.org
Imatinib has revolutionized drug therapy of chronic myeloid leukemia (CML). Preclinical
studies were promising but the results of clinical trials by far exceeded expectations …
studies were promising but the results of clinical trials by far exceeded expectations …
Graft-versus-leukemia effects of transplantation and donor lymphocytes
HJ Kolb - Blood, The Journal of the American Society of …, 2008 - ashpublications.org
Allogeneic transplantation of hematopoietic cells is an effective treatment of leukemia, even
in advanced stages. Allogeneic lymphocytes produce a strong graft-versus-leukemia (GVL) …
in advanced stages. Allogeneic lymphocytes produce a strong graft-versus-leukemia (GVL) …
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
Most patients with chronic myeloid leukemia (CML) treated with imatinib will relapse if
treatment is withdrawn. We conducted a prospective clinical trial of imatinib withdrawal in 40 …
treatment is withdrawn. We conducted a prospective clinical trial of imatinib withdrawal in 40 …
Chronic myeloid leukaemia
R Hehlmann, A Hochhaus, M Baccarani - The Lancet, 2007 - thelancet.com
Chronic myeloid leukaemia (CML) was the first neoplastic disease for which knowledge of
the genotype led to a rationally designed therapy. As a result of its well known …
the genotype led to a rationally designed therapy. As a result of its well known …
CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors
A Hughes, J Clarson, C Tang, L Vidovic… - Blood, The Journal …, 2017 - ashpublications.org
Immunological control may contribute to achievement of deep molecular response in chronic
myeloid leukemia (CML) patients on tyrosine kinase inhibitor (TKI) therapy and may promote …
myeloid leukemia (CML) patients on tyrosine kinase inhibitor (TKI) therapy and may promote …
Pushing the limits of targeted therapy in chronic myeloid leukaemia
T O'hare, MS Zabriskie, AM Eiring… - Nature Reviews …, 2012 - nature.com
Tyrosine kinase inhibitor (TKI) therapy targeting the BCR-ABL1 kinase is effective against
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …
Molecules and mechanisms of the graft-versus-leukaemia effect
M Bleakley, SR Riddell - Nature Reviews Cancer, 2004 - nature.com
The ability of allogeneic bone-marrow cells and peripheral-blood stem cells to cure
leukaemia remains the most striking example of the ability of the human immune system to …
leukaemia remains the most striking example of the ability of the human immune system to …
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA …
Abstract Around 40–50% of patients with chronic myeloid leukemia (CML) who achieve a
stable complete molecular response (CMR; undetectable breakpoint cluster region-Abelson …
stable complete molecular response (CMR; undetectable breakpoint cluster region-Abelson …
[HTML][HTML] Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation
J Huuhtanen, S Adnan-Awad, J Theodoropoulos… - Leukemia, 2024 - nature.com
Immunological control of residual leukemia cells is thought to occur in patients with chronic
myeloid leukemia (CML) that maintain treatment-free remission (TFR) following tyrosine …
myeloid leukemia (CML) that maintain treatment-free remission (TFR) following tyrosine …
[HTML][HTML] Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID …
SE Lee, SY Choi, HY Song, SH Kim, MY Choi… - …, 2016 - ncbi.nlm.nih.gov
The aim of the Korean Imatinib Discontinuation Study was to identify predictors for safe and
successful imatinib discontinuation. A total of 90 patients with a follow-up of≥ 12 months …
successful imatinib discontinuation. A total of 90 patients with a follow-up of≥ 12 months …